Latest Articles
Cardiac damage framework may identify patients who could benefit from earlier TAVR - MSN
Cardiac damage framework may identify patients who could benefit from earlier TAVR MSN
Published: Oct. 31, 2024, 6:39 a.m.
ScotRail becomes endometriosis-friendly employer - Employee Benefits
ScotRail becomes endometriosis-friendly employer Employee Benefits
Published: Oct. 28, 2024, 11:05 a.m.
Endometriosis Patient to Host EMO Music Fundraiser in Columbus, Ohio, to Benefit EndoFound - Endometriosis Foundation of America - The Blossom
Endometriosis Patient to Host EMO Music Fundraiser in Columbus, Ohio, to Benefit EndoFound Endometriosis Foundation of America - The Blossom
Published: Oct. 23, 2024, 8:39 p.m.
Danielle Collins Refuses to End 'DANIMAL' Chapter in a Defiant U-Turn on Retirement Amid Ongoing Endometriosis Battle - MSN
Danielle Collins Refuses to End 'DANIMAL' Chapter in a Defiant U-Turn on Retirement Amid Ongoing Endometriosis Battle MSN
Published: Oct. 19, 2024, 5:15 p.m.
Danielle Collins Refuses to End ‘DANIMAL’ Chapter in a Defiant U-Turn on Retirement Amid Ongoing Endometriosis Battle - EssentiallySports
Danielle Collins Refuses to End ‘DANIMAL’ Chapter in a Defiant U-Turn on Retirement Amid Ongoing Endometriosis Battle EssentiallySports
Published: Oct. 18, 2024, 3:11 a.m.
Gender questions on healthcare benefits - Corporate Adviser
Gender questions on healthcare benefits Corporate Adviser
Published: Oct. 15, 2024, 3:48 p.m.
Dostarlimab/Chemo Shows OS Benefit Regardless of MMR Status in Endometrial Cancer - OncLive
Dostarlimab/Chemo Shows OS Benefit Regardless of MMR Status in Endometrial Cancer OncLive
Published: July 3, 2024, 7 a.m.
FDA Approves AstraZeneca’s Imfinzi for Mismatch Repair Deficient Primary Advanced or Recurrent Endometrial Cancer - Pharmaceutical Executive
FDA Approves AstraZeneca’s Imfinzi for Mismatch Repair Deficient Primary Advanced or Recurrent Endometrial Cancer Pharmaceutical Executive
Published: June 17, 2024, 7 a.m.
Study Misses Endpoints but Still Shows Benefit for Lenvatinib/Pembrolizumab in Endometrial Cancer Subsets - The ASCO Post
Study Misses Endpoints but Still Shows Benefit for Lenvatinib/Pembrolizumab in Endometrial Cancer Subsets The ASCO Post
Published: June 10, 2024, 7 a.m.
NLRC5 promotes endometrial carcinoma progression by regulating NF-κB pathway-mediated mismatch repair gene deficiency - Nature.com
NLRC5 promotes endometrial carcinoma progression by regulating NF-κB pathway-mediated mismatch repair gene deficiency Nature.com
Published: May 30, 2024, 7 a.m.
Link copied to clipboard!